This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Roeland Vanhauwaert, PhD
Senior Scientist at Argenx


Experienced neuroscientist specialized in neurodegeneration and neuromuscular biology. I obtained my PhD at KU Leuven/VIB Belgium (2017), followed by a 2 year post-doc at Stanford University. I’ve obtained competitive fellowship for both doctoral and post-doctoral. At Stanford University, I was responsible for translational research and drug discovery for neurodegenerative diseases, especially Parkinson’s disease. I was leading a small team, aiming to develop a partial Miro1 inhibitor to ultimately cure Parkinson’s disease. My research results are the foundation of a start-up company in Silicon Valley. Since 2019, I’m lead senior scientist for the ARGX-119 program at argenx.

Agenda Sessions

  • ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease